Trial Profile
Global phase III trial of BOW050 [adalimumab biosimilar] in patients with autoimmune disorders
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2016 According to an Epirus media release, global regulatory filing for BOW-050 is expected in 2018.
- 11 Aug 2015 New trial record